Financial Lp Hrt Sells 34,938 Shares of Bluejay Diagnostics (NASDAQ:BJDX) Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) major shareholder Financial Lp Hrt sold 34,938 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $1.40, for a total transaction of $48,913.20. Following the completion of the sale, the insider owned 92,055 shares of the company’s stock, valued at $128,877. The trade was a 27.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, July 9th, Financial Lp Hrt purchased 64,047 shares of Bluejay Diagnostics stock. The stock was bought at an average cost of $1.51 per share, with a total value of $96,710.97.

Bluejay Diagnostics Stock Performance

Shares of NASDAQ BJDX traded down $0.23 during trading on Monday, hitting $1.22. 973,437 shares of the company traded hands, compared to its average volume of 1,803,857. The business’s fifty day moving average is $2.69 and its 200 day moving average is $2.49. Bluejay Diagnostics, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $16.68. The firm has a market capitalization of $1.26 million, a price-to-earnings ratio of -0.10 and a beta of 0.88.

Bluejay Diagnostics (NASDAQ:BJDX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

Institutional Trading of Bluejay Diagnostics

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.